Kinfo
Ginkgo Bioworks Holdings, Inc. Class A Common Stock logo

Ginkgo Bioworks Holdings, Inc. Class A Common Stock

DNANYSEHealthcare·US · USD
$12.35
-0.15 (-1.20%)
Prices as of October 2, 2026 · market closed

Price

Key statistics

Valuation
Market cap831.65M USD
Enterprise value943.70M USD
Trailing P/E-2.19
Forward P/E-4.31
PEG ratio0.07
Price / sales6.36
Price / book1.89
Profitability
Gross margin91.47%
Operating margin-284.99%
Profit margin-219.61%
Return on assets-16.72%
Return on equity-59.94%
Income (TTM)
Revenue132.42M USD
Gross profit90.10M USD
EBITDA-261.62M USD
Net income-309.64M USD
Diluted EPS-$5.19
Rev. growth (YoY)-48.50%
Balance sheet
Total cash302.16M USD
Total debt404.11M USD
Debt / equity96.15
Current ratio4.57
Book value / share$6.60
Cash flow (TTM)
Operating cash flow-170.24M USD
Levered free cash flow-72.40M USD
Shares & price
Shares outstanding63.71M
Float49.88M
Held by institutions73.73%
Beta1.77
50-day MA$7.89
200-day MA$8.29
52-week high$17.58
52-week low$5.37
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-05-0.70-0.73−4.29%2026-05-07-1.34-1.39−3.73%2026-02-26-1.11-0.77+30.63%2025-11-193.213.63+13.08%2025-11-06-1.24-1.45−16.94%
About Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Ginkgo Bioworks Holdings, Inc. Class A Common Stock represents ownership in Ginkgo Bioworks Holdings, a biotechnology company focused on cell engineering and biological design. Ginkgo Bioworks develops a platform that helps customers design, build, and test custom microbes and other biological systems for use in industries such as pharmaceuticals, agriculture, food, industrial chemicals, and specialty materials. The company provides biological R&D services, automation-enabled laboratory tools, and data-driven software that support the research, development, and commercialization of engineered organisms. It also serves government and commercial clients through biosecurity-related offerings that support biological monitoring and surveillance. Headquartered in Boston, Massachusetts, Ginkgo Bioworks plays a specialized role in the life sciences market by supplying infrastructure and services that make biological engineering more accessible across multiple sectors.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jason Kelly Ph.D.
Employees
485
Headquarters
Boston, MA, United States

Frequently asked questions about Ginkgo Bioworks Holdings, Inc. Class A Common Stock